Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

Journal of Clinical Oncology

Volumn 22, Issue 7, 2004, Pages 1209-1214

  Grothey, Axel ^a   Sargent, Daniel ^a   Goldberg, Richard M ^a   Schmoll, Hans Joachim ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; META ANALYSIS; MORTALITY; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 2142703727     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.11.037     Document Type: Article

References (22)

1. Grothey A, Schmoll HJ: New chemotherapy approaches in colorectal cancer. Curr Opin Oncol 13:275-286, 2001
2. Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
3. Koehne C, Van Cutsem E, Wils J, et al: Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC G1 Group study 40986. Proc Am Soc Clin Oncol 22:254, 2003 (abstr 1018)
4. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097-4106, 2001
5. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001
6. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998
7. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
8. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
9. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
10. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
11. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
12. Grothey A, Deschler B. Kroening H, et al: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 21:129a, 2002 (abstr 512)
13. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
14. Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21:2059-2069, 2003
15. Douillard JY, Hoff PM. Skillings JR, et al: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605-3616, 2002
16. Carmichael J, Popiela T, Radstone D, et al: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617-3627, 2002
17. Maughan TS, James RD, Kerr DJ, et al: Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicentre randomised trial. Lancet 361:457-464, 2003
18. Morton R, Goldberg R, Sargent D, et al: Oxaliplatin (OXAL) or CPT-11 combined with 5FU/leucovorin (LV) in advanced colorectal cancer (CRC): An NCCTG/CALGB study. Proc Am Soc Clin Oncol 20:125a, 2001 (abstr 495)
19. Roth A, Seium Y, Ruhstaller T, et al: Oxaliplatin (OXA) combined with irinotecan (CPT-11) and 5FU/leucovorin (OCFL) in metastatic colorectal cancer (MCRC): A phase I-II study. Proc Am Soc Clin Oncol 21:143a, 2002 (abstr 570)
20. Souglakos J, Mavroudis D, Kakolyris S, et al: Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial. J Clin Oncol 20:2651-2657, 2002
21. Masi G, Allegrini G, Danesi R, et al: Bi-weekly irinotecan (CPT-11), oxaliplatin (LOHP), leucovorin (LV) and 5-fluorouracil (5-FU) 48 hrs. continuous infusion in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 21:169a. 2002 (abstr 673)
22. Falcone A, Masi G, Allegrini G, et al: Bi-weekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: A pilot study in patients with metastatic colorectal cancer. J Clin Oncol 20:4006-4014, 2002